- 全部删除
 
您的购物车当前为空
SEP-363856 是一种口服活性和 CNS 活性的精神药物,具有独特的非 D2/5-HT2A 作用机制,发挥其抗精神病样作用,具有治疗精神分裂症的潜力。

SEP-363856 是一种口服活性和 CNS 活性的精神药物,具有独特的非 D2/5-HT2A 作用机制,发挥其抗精神病样作用,具有治疗精神分裂症的潜力。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 25 mg | ¥ 10,600  | 1-2周 | |
| 50 mg | ¥ 13,800  | 1-2周 | |
| 100 mg | ¥ 17,500  | 1-2周 | 
SEP-363856 相关产品
| 产品描述 | SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia.  | 
| 靶点活性 |  5-HT1D receptor:0.262 μM (EC50), 5-HT1B receptor:15.6 μM (EC50), TAAR1:0.140 μM (EC50), 5-HT1A receptor:2.3 μM (EC50), 5-HT7 receptor:6.7 μM (EC50), 5-HT2A receptor:10 μM (EC50), 5-HT2C receptor:30 μM (EC50)  | 
| 体外活性 | SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor.  | 
| 体内活性 | SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active. SEP-856 exhibits a behavioral signature similar to known antipsychotic drugs.PCP-induced hyperactivitysignificantly reduced by SEP-856 (0.3, 1 and 10 mg/kg, orally once) . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time.  | 
| 别名 | SEP-856 | 
| 分子量 | 183.27 | 
| 分子式 | C9H13NOS | 
| CAS No. | 1310426-33-5 | 
| 密度 | 1.123 g/cm3 (Predicted) | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | 
评论内容